GLP-1 Medicines and NAION: What Is the Current Evidence on Vision Risk?
Current September 2026 evidence on GLP-1 medicines, semaglutide, tirzepatide and NAION, including absolute risk, safety guidance and what patients should do about sudden vision loss.
